Key facts
- This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Feb 2024, 13:36.
John E. Imhoff - 16 Oct 2023 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- GTHP
- Reported as of
- 16 Oct 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Feb 2024, 13:36:25 UTC
- Prior SEC filing
- 07 Sep 2023
- Next SEC filing
- 19 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John E. Imhoff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John E. Imhoff filed Form 4 for GUIDED THERAPEUTICS INC (GTHP) on 22 Feb 2024.
Change
- Previous filing in this sequence was filed on 07 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GTHP
transaction
Common Stock
Other
- Transaction value
- Shares
- +37,410
- Change %
- +0.74%
- Price
- Shares after
- 5,087,514
- Date
- 16 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
GTHP
transaction
Common Stock
Other
- Transaction value
- Shares
- +37,324
- Change %
- +0.73%
- Price
- Shares after
- 5,124,838
- Date
- 16 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1504.
Footnote F2
These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1507.